Skip to main content
SpringerLink
Log in

Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Left ventricular hypertrophy (LVH) is a major cardiovascular risk factor for morbidity and mortality. It is caused by arterial hypertension, although various hemodynamic and nonhemodynamic factors contribute to its development. Especially, the renin-angiotensin-aldosterone system is involved in the pathophysiology of LVH. The Treatment of Mild Hypertension study demonstrated that in mild essential hypertension, nonpharmacologic treatment is an effective tool for treating LVH. There are at least three major meta-analyses with several thousand patients examining the ability of antihypertensive drugs on the reversal of LVH. The results of these meta-analyses are very consistent. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers achieve significantly better results than β-blockers. The most recently published Losartan Intervention For Endpoint reduction in hypertension study confirmed the superiority of angiotensin receptor blockers against β-blockers in a large-scale prospective trial. It also proves for the first time that regression of LVH is associated with better cardiovascular outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Savage DD, Levy D, Dannenberg AL, et al.: Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol 1990, 65:371–376. The link between blood pressure and LVH is explored in this publication.

    Article  PubMed  CAS  Google Scholar 

  2. Levy D, Anderson KM, Savage DD, et al.: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988, 108:7–13. Important epidemiologic data on prevalence and risk factors of LVH.

    PubMed  CAS  Google Scholar 

  3. Ghali JK, Liao Y, Simmons B, et al.: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992, 117:831–836.

    PubMed  CAS  Google Scholar 

  4. Koren MJ, Devereux RB, Casale PN, et al.: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991, 114:345–352.

    PubMed  CAS  Google Scholar 

  5. Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–566. The implication of LVH on morbidity and mortality is highlighted. This publication underscores the clinical importance of LVH.

    Article  PubMed  CAS  Google Scholar 

  6. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977, 55:613–618.

    PubMed  CAS  Google Scholar 

  7. Devereux RB, Lutas EM, Casale PN, et al.: Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984, 4:1222–1230.

    Article  PubMed  CAS  Google Scholar 

  8. Dahlof B, Devereux R, de Faire U, et al.: The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997, 10:705–713. Most recent trial comparing losartan and atenolol and their potential to prevent cardiovascular events in patients with electrocardiographic LVH.

    Article  PubMed  CAS  Google Scholar 

  9. White WB, Schulman P, McCabe EJ, Dey HM: Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA 1989, 261:873–877.

    Article  PubMed  CAS  Google Scholar 

  10. Verdecchia P, Schillaci G, Guerrieri M, et al.: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990, 81:528–536.

    PubMed  CAS  Google Scholar 

  11. Chen CH, Ting CT, Lin SJ, et al.: Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995, 25:1034–1041.

    PubMed  CAS  Google Scholar 

  12. Saba PS, Roman MJ, Pini R, et al.: Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 1993, 22:1873–1880.

    Article  PubMed  CAS  Google Scholar 

  13. Chien S, Li S, Shyy YJ: Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 1998, 31:162–169. This paper elucidates the pathway of signal induction, which is started by mechanical forces such as shear stress.

    PubMed  CAS  Google Scholar 

  14. Molkentin JD: Calcineurin and beyond: Cardiac hypertrophic signaling Circ Res 2000, 87:731–738. An excellent review on the pathophysiologic mechanisms of the calcineurin pathway for cardiac hypertrophy.

    PubMed  CAS  Google Scholar 

  15. Douglas PS, Katz SE, Weinberg EO, et al.: Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 1998, 32:1118–1125.

    Article  PubMed  CAS  Google Scholar 

  16. Hammond IW, Alderman MH, Devereux RB, et al.: Contrast in cardiac anatomy and function between black and white patients with hypertension. J Natl Med Assoc 1984, 76:247–255.

    PubMed  CAS  Google Scholar 

  17. Schmieder RE EJ, Delles C, Jacobi J, et al.: Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 2001, 37:175–182.

    Article  PubMed  CAS  Google Scholar 

  18. Lauer MS, Anderson KM, Levy D: Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 1992, 19:130–134. The influence of obesity on LVH is investigated in this publication.

    Article  PubMed  CAS  Google Scholar 

  19. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD: Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation 1988, 78:951–956.

    PubMed  CAS  Google Scholar 

  20. Schmieder RE, Langenfeld MR, Friedrich A, et al.: Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996, 94:1304–1309. This publication underscores the impact of angiotensin II on the development of LVH in humans.

    PubMed  CAS  Google Scholar 

  21. Schlaich MP, Schobel HP, Langenfeld MR, et al.: Inadequate suppression of angiotensin II modulates left ventricular structure in humans. Clin Nephrol 1998, 49:153–159.

    PubMed  CAS  Google Scholar 

  22. Trimarco B, Ricciardelli B, De Luca N, et al.: Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents. Circulation 1985, 72:38–46.

    PubMed  CAS  Google Scholar 

  23. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992, 5:95–110.

    PubMed  CAS  Google Scholar 

  24. Jennings G, Wong J: Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment. In Handbook of Hypertension, vol 18. Edited by Hansson L, Birkenhäger W. Amsterdam: Elsevier Science; 1997:184–223.

    Google Scholar 

  25. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507–1513. Important meta-analysis on the impact of various drug classes on regression of LVH, including ACE inhibitors.

    Article  PubMed  CAS  Google Scholar 

  26. Schmieder RE, Schlaich MP: Comparison of therapeutic studies on regression of left ventricular hypertrophy. Adv Exp Med Biol 1997, 432:191–198.

    PubMed  CAS  Google Scholar 

  27. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P: Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998, 13:564–569.

    Article  PubMed  CAS  Google Scholar 

  28. Klingbeil AU, Schneider M, Martus P, et al.: Reduction of left ventricular mass in essential hypertension. Am J Med 2002, in press.

  29. Terpstra WF, May JF, Smit AJ, et al.: Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001, 19:303–309.

    Article  PubMed  CAS  Google Scholar 

  30. De Rosa ML, Cardace P, Rossi M, et al.: Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002, 16:133–140.

    Article  PubMed  CAS  Google Scholar 

  31. Malmqvist K, Kahan T, Edner M, et al.: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001, 19:1167–1176.

    Article  PubMed  CAS  Google Scholar 

  32. Liebson PR, Grandits GA, Dianzumba S, et al.: Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995, 91:698–706. Lifestyle modulation is identified as powerful treatment for LVH, as beneficial as pharmacologic treatment.

    PubMed  CAS  Google Scholar 

  33. Dahlof B, Devereux RB, Julius S, et al.: Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998, 32:989–997.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine 4/IV, University of Erlangen-Nuremberg, Breslauer Strasse 201, 90475, Nuremberg, Germany

    Erwin H. Fleischmann MD & Roland E. Schmieder MD

Authors
  1. Erwin H. Fleischmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland E. Schmieder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleischmann, E.H., Schmieder, R.E. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?. Curr Cardiol Rep 4, 474–478 (2002). https://doi.org/10.1007/s11886-002-0109-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-002-0109-2

Keywords

Search

Navigation